QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and raises the price target fr...

Core News & Articles

Oppenheimer analyst Leland Gershell reiterates enGene Holdings (NASDAQ:ENGN) with a Outperform and raises the price target f...

Core News & Articles

UBS analyst Colin Bristow maintains enGene Holdings (NASDAQ:ENGN) with a Neutral and raises the price target from $4 to $10.

Core News & Articles

Citizens analyst Silvan Tuerkcan maintains enGene Holdings (NASDAQ:ENGN) with a Market Outperform and raises the price targe...

 engene-encouraged-by-promising-response-rates-in-bladder-cancer-trial

enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.

Core News & Articles

enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and lowers the price target fr...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with a Buy and maintains $25 pr...

Core News & Articles

enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with a Buy and maintains $25 pr...

Core News & Articles

Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achievedenGene plans to provide an update fro...

Core News & Articles

Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development toolsDesignation recognize...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION